INT192951
From wiki-pain
|
|
|
|
|
Sentences Mentioned In
Key: | Protein | Mutation | Event | Anatomy | Negation | Speculation | Pain term | Disease term |
The greatest reduction in the number of GI AEs was seen in those subjects who remained on a dose of 20 mg taspoglutide throughout the study. | |||||||||||||||
| |||||||||||||||
|
For migraineurs, the most important attributes of acute treatments are complete pain relief, lack of recurrence, rapid onset of action, and absence of AEs. | |||||||||||||||
| |||||||||||||||
|
Reducing these nuisance AEs can lead to increased tolerability, compliance and patient satisfaction. | |||||||||||||||
| |||||||||||||||
|
Recommended supportive care measures for managing AEs associated with bisphosphonate therapy are presented in Table 1.2,25,26
Quality of life | |||||||||||||||
| |||||||||||||||
|
8 fluid oz (237 mL) water after an overnight fast and not reclining, eating, or drinking for 3060 minutes after dosing) reduces UGI AEs and enhances absorption. | |||||||||||||||
| |||||||||||||||
|
He focused on other issues that could be determinant for patients in the long term, such as Progression in Adulthood (PiA), Breathing Function (BF) (in terms of survival), function in life (marrying, child-bearing, employment, depression, Back Pain [BP], Dis, Aes, neurological impairment). | |||||||||||||||
| |||||||||||||||
|
The highest number of AEs occurred during the first 26 weeks of treatment with infliximab (Figure 2a). | |||||||||||||||
| |||||||||||||||
|
A number of the AEs related to treatment were indicative of perioperative infection which is not unexpected with treatments procedures in the anorectal region [53]. | |||||||||||||||
| |||||||||||||||
|
Similarly, during 4 years of dutasteride treatment there was a trend towards a reduction in the rate of newly reported sexual AEs over time (51). | |||||||||||||||
| |||||||||||||||
|
QoL improved over time from 68.8% to 72.7% (P = 0.042) as well, and was significantly associated with the perception of health status, presence of adverse events (AEs) and number of reported AEs (P < 0.0001). | |||||||||||||||
| |||||||||||||||
|
However, source data verification of 10% of patients did not suggest that a significant number of AEs were missed, with a similar occurrence of events reported for patients with different end digits of their patient number (Chi-squared test, p = 0.8). | |||||||||||||||
| |||||||||||||||
|
The number of AEs that occurred in the 40 and 80 mg groups were statistically significantly greater compared with the placebo group (P < 0.05 for both groups) (Table 4). | |||||||||||||||
| |||||||||||||||
|
Exact JonckheereTerpstra (J-T) tests were performed to examine dose-response relationships for adverse events, according to dose of AMA1-C1 vaccine (control, low dose, and high dose) for each category of AE and total number of AEs. | |||||||||||||||
| |||||||||||||||
|
Differences between adjuvant or dose groups were analyzed by Fisher's exact test for safety and reactogenicity data (numbers of AEs). | |||||||||||||||
| |||||||||||||||
|
Unsolicited local and general AEs were monitored up to 30 d after injection in diary cards, but had to be reported anytime during the whole trial at each visit. | |||||||||||||||
| |||||||||||||||
|
General Comments
This test has worked.